Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma

Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma. Methods: We undertook an analysis of eight relevant published docum...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Xavier Armoiry, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe, Claude Dussart
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis Group 2019-01-01
Sarja:Journal of Market Access & Health Policy
Aiheet:
nice
has
health technology assessment
france
england
ixazomib
multiple myeloma
Linkit:http://dx.doi.org/10.1080/20016689.2019.1648971
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia